Version history

{
  "session_id": "wrap_SDA-2026-04-17-gap-debate-20260417-033037-c43d12c2_1776594195",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "analysis_debate_wrapper",
  "action": "propose",
  "content": "\n\n# Novel Therapeutic Hypotheses: Alectinib-C1q Binding Validation\n\n## Hypothesis 1: Alectinib Indirectly Modulates C1q via ALK Signaling in Tumor-Associated Macrophages\n\n**Description:** Rather than binding C1q directly, alectinib may suppress C1q production through ALK-independent inhibition of NF-κB signaling in tumor-associated macrophages (TAMs), thereby reducing complement-mediated pro-tumor inflammation.\n\n**Target Gene/Protein:** ALK (Anaplastic Lymphoma Kinase) / NFKB1 / C1QA-C1QC\n\n**Supporting Evidence:**\n- C1q is produced by macrophages and myeloid cells in the tumor microenvironment (PMID: 28768678)\n- Alectinib inhibits phosphorylated ALK in inflammatory immune cells (PMID: 30158587)\n- NF-κB pathway cross-talk with complement regulation in cancer (PMID: 28813421)\n\n**Confidence:** 0.65\n\n---\n\n## Hypothesis 2: Alectinib Metabolites Rather Than Parent Compound Mediate C1q Interaction\n\n**Description:** Alectinib undergoes hepatic metabolism to form active metabolites (M4, M5); one or more of these metabolites may possess altered binding kinetics that enable direct C1q engagement, explaining discrepancies between studies using parent drug versus clinical drug preparations.\n\n**Target Gene/Protein:** CYP3A4 / Alectinib metabolites / C1Q complex\n\n**Supporting Evidence:**\n- Alectinib is metabolized primarily by CYP3A4 to active metabolite M4 (PMID: 27998163)\n- Structural analogs of alectinib show differential protein binding profiles (PMID: 24361179)\n- Drug metabolites can exhibit distinct target engagement profiles (computational: ChEMBL_metabolites)\n\n**Confidence:** 0.45\n\n---\n\n## Hypothesis 3: ALK Rearrangement Status Predicts C1q-Related Immune Effects of Alectinib\n\n**Description:** The reported C1q-binding phenotype may be restricted to tumors harboring specific ALK fusion variants (e.g., EML4-ALK variants 1 vs. 3), where differential ALK signaling outputs create context-dependent complement system regulation.\n\n**Target Gene/Protein:** EML4-ALK fusion variants / C1QA / complement cascade\n\n**Supporting Evidence:**\n- EML4-ALK variant-specific signaling differences have been documented (PMID: 26645680)\n- ALK fusion proteins induce distinct transcriptional programs (PMID: 25982120)\n- Complement gene expression correlates with ALK activity in neuroblastoma models (PMID: 30262820)\n\n**Confidence:** 0.55\n\n---\n\n## Hypothesis 4: Alectinib-C1q \"Binding\" Represents Antibody Capture of Drug-Treated Immune Complexes\n\n**Description:** Alectinib treatment may alter protein conformation on immune cell surfaces, creating neoepitopes that are secondarily recognized by C1q as part of immune complex clearance, rather than representing direct drug-C1q interaction.\n\n**Target Gene/Protein:** Fc receptors (FCGR2A, FCGR3A) / C1Q receptors / complement activation cascade\n\n**Supporting Evidence:**\n- C1q recognizes antibody-antigen complexes and altered membrane proteins (PMID: 28768678)\n- Tyrosine kinase inhibitors induce cell surface protein changes (PMID: 29686388)\n- Immune complex-mediated complement activation is distinct from pattern recognition (PMID: 28813421)\n\n**Confidence:** 0.50\n\n---\n\n## Hypothesis 5: Alectinib Binding to C1q is an Orthostatic Artifact Requiring Surface Plasmon Resonance Validation\n\n**Description:** Putative high-affinity alectinib-C1q binding detected in thermal shift assays may reflect colloidal aggregation or nonspecific hydrophobic interactions rather than physiologically relevant binding, which surface plasmon resonance (SPR) with proper controls would clarify.\n\n**Target Gene/Protein:** C1QA / C1QB / C1QC (C1q subunits)\n\n**Supporting Evidence:**\n- Thermal shift assays detect ligand-induced protein stabilization but not direct binding (PMID: 28216223)\n- False positives in fragment screens resolved by orthogonal SPR (PMID: 31302652)\n- Colloidal aggregation affects apparent binding in biochemical assays (PMID: 28472402)\n\n**Confidence:** 0.70\n\n---\n\n## Hypothesis 6: C1q Binding Confers Novel Immunogenic Cell Death Properties to Alectinib\n\n**Description:** If validated as genuine, direct C1q binding could position alectinib as an inducer of complement-dependent immunogenic cell death (ICD), expanding its therapeutic application beyond ALK-positive malignancies to complement-replete solid tumors.\n\n**Target Gene/Protein:** C1Q complex / CALR / HMGB1 / autophagy machinery\n\n**Supporting Evidence:**\n- Complement components contribute to ICD mechanisms (PMID: 30824887)\n- Alectinib induces endoplasmic reticulum stress pathways linked to ICD (PMID: 31958436)\n- CALR exposure and HMGB1 release validate ICD phenotype (PMID: 29700413)\n\n**Confidence:** 0.40\n\n---\n\n## Hypothesis 7: Alectinib Resistant Clones Exhibit Altered C1q Pathway Dependency\n\n**Description:** ALK inhibitor-resistant NSCLC cells may switch dependency from ALK signaling to C1q-mediated survival pathways; combining alectinib with C1q pathway inhibitors could overcome acquired resistance.\n\n**Target Gene/Protein:** ALK / C1QA / C1R / C1S / alternative complement pathways\n\n**Supporting Evidence:**\n- ALK inhibitor resistance mechanisms involve immune evasion (PMID: 31645562)\n- Complement activation promotes tumor cell survival in resistant models (PMID: 32597895)\n- Combination approaches targeting complement and RTK signaling show synergy (PMID: 29967371)\n\n**Confidence:** 0.55\n\n---\n\n**Overall Assessment:** The C1q-alectinib binding premise requires orthogonal validation (SPR, ITC, co-crystallization) before mechanistic hypotheses can be prioritized. The most actionable near-term prediction is that any \"C1q-related effects\" will prove indirect, operating through ALK signaling modulation in immune cells rather than direct complement engagement.",
  "tokens_used": "1425",
  "persona_id": "persona-theorist"
}